BiomX Inc. (PHGE)
NYSEAMERICAN: PHGE · Real-Time Price · USD
0.5170
-0.0002 (-0.04%)
At close: Sep 5, 2025, 4:00 PM
0.5118
-0.0052 (-1.01%)
After-hours: Sep 5, 2025, 8:00 PM EDT

Company Description

BiomX Inc., a clinical-stage biopharmaceutical company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic diseases.

The company is developing BX211, a phage therapy, which is in phase 2 clinical study for the treatment of diabetic foot osteomyelitis.

It also developing BX004, a phage therapy for cystic fibrosis and non-cystic fibrosis bronchiectasis patients with chronic pulmonary infections caused by Pseudomonas aeruginosa that is in Phase 1b/2a clinical trials.

The company was founded in 2015 and is headquartered in Ness Ziona, Israel.

BiomX Inc.
BiomX logo
CountryIsrael
Founded2015
IndustryBiotechnology
SectorHealthcare
Employees57
CEOJonathan Solomon

Contact Details

Address:
22 Einstein Street, Floor 4
Ness Ziona, 7414003
Israel
Phone972 7 2394 2377
Websitebiomx.com

Stock Details

Ticker SymbolPHGE
ExchangeNYSEAMERICAN
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0001739174
CUSIP Number09090D103
ISIN NumberUS09090D3017
Employer ID82-3364020
SIC Code2836

Key Executives

NamePosition
Jonathan Eitan Solomon MBAChief Executive Officer and Director
Marina Wolfson CPAChief Financial Officer and Secretary
Dr. Merav Bassan Ph.D.Chief Development Officer
Prof. Rotem Sorek Ph.D.Scientific Founder
Dr. Eran Elinav M.D., Ph.D.Scientific Founder
Dr. Timothy K. Lu M.D., Ph.D.Scientific Founder
Inbal Benjamini-ElranC.H.R.O

Latest SEC Filings

DateTypeTitle
Aug 28, 2025ARSFiling
Aug 28, 2025DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) material
Aug 28, 2025DEF 14AOther definitive proxy statements
Aug 19, 20258-KCurrent Report
Aug 15, 2025PRE 14AOther preliminary proxy statements
Aug 13, 2025424B5Filing
Aug 13, 202510-QQuarterly Report
Aug 13, 20258-KCurrent Report
Aug 7, 2025SCHEDULE 13G/AFiling
Aug 5, 2025SCHEDULE 13GFiling